The software of life is how Moderna Inc. CEO Stephane Bancel describes messenger RNA (mRNA), which is at the core of the company’s drug development process.
Biogen is discontinuing development of an experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a medicine for the disorder.
Novartis AG won U.S. approval for the company’s experimental sickle cell disease drug Adakveo.
Amarin Corp. Plc’s fish oil-derived drug and potential blockbuster Vascepa received a largely positive review from FDA staffers.
Johnson & Johnson’s Spravato, a nasal spray for depression and potential blockbuster medicine, won recommendation for approval from a European Medicines Agency panel.
Denmark’s Lundbeck agreed to buy Alder BioPharmaceuticals in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.
Novartis Chief Executive Officer Vas Narasimhan is excited about the path the Swiss pharma giant is taking, particularly as the company is heading into what is seen as an “exciting growth phase” featuring multiple drug launches.
Novartis has 25 potential blockbuster treatments in development, the company said ahead of a management event in the United States.
The U.S. Food and Drug Administration approved Pfizer Inc.’s oral drug tafamidis to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy.
Horizon Pharma’s late-stage treatment teprotumumab for active thyroid eye disease continues to demonstrate greater efficacy. Two months after releasing positive Phase III data, the company shared additional secondary endpoint data that shows higher levels of patient benefit.